IDEAYA Biosciences Inc
IDYA25.020USD
+0.520+2.12%
Handelsschluss 07/28, 16:00（ET）Kurse um 15 Minuten verzögert
2.19BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über IDEAYA Biosciences Inc Unternehmen
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
Unternehmensinformationen
BörsenkürzelIDYA
Name des UnternehmensIDEAYA Biosciences Inc
IPO-datumMay 23, 2019
Gegründet am2015
CEOMr. Yujiro S. Hata
Anzahl der mitarbeiter131
WertpapierartOrdinary Share
GeschäftsjahresendeMay 23
Addresse7000 Shoreline Ct, Suite 350
StadtSOUTH SAN FRANCISCO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94080
Telefon16504436209
Websitehttps://www.ideayabio.com/
BörsenkürzelIDYA
IPO-datumMay 23, 2019
Gegründet am2015
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Dr. Michael A. White, Ph.D.
Dr. Michael A. White, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2024
FY2024Q4
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
Nach RegionUSD
Name
Umsatz
Anteil
United States
7.00M
100.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
Aktionärsstatistik
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
14.99%
BlackRock Institutional Trust Company, N.A.
8.17%
Janus Henderson Investors
7.31%
The Vanguard Group, Inc.
5.80%
Federated Hermes Global Investment Management Corp.
5.44%
Other
58.29%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
14.99%
BlackRock Institutional Trust Company, N.A.
8.17%
Janus Henderson Investors
7.31%
The Vanguard Group, Inc.
5.80%
Federated Hermes Global Investment Management Corp.
5.44%
Other
58.29%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
45.54%
Investment Advisor/Hedge Fund
33.49%
Hedge Fund
21.64%
Venture Capital
8.56%
Research Firm
4.37%
Individual Investor
0.91%
Pension Fund
0.77%
Sovereign Wealth Fund
0.59%
Bank and Trust
0.34%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
444
101.86M
116.30%
-6.31M
2025Q1
454
97.81M
111.68%
-11.15M
2024Q4
442
95.26M
108.96%
-7.87M
2024Q3
426
95.20M
112.79%
+2.56M
2024Q2
409
85.26M
112.59%
-3.91M
2024Q1
388
81.45M
108.91%
-1.44M
2023Q4
351
68.31M
105.94%
-512.62K
2023Q3
331
61.92M
105.66%
-3.64M
2023Q2
313
59.35M
103.37%
+5.88M
2023Q1
290
47.36M
97.90%
-6.95M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
13.13M
14.99%
+167.11K
+1.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.15M
8.17%
+286.75K
+4.18%
Mar 31, 2025
Janus Henderson Investors
6.40M
7.31%
+544.14K
+9.29%
Mar 31, 2025
The Vanguard Group, Inc.
5.08M
5.8%
+14.54K
+0.29%
Mar 31, 2025
Federated Hermes Global Investment Management Corp.
4.77M
5.44%
-295.60K
-5.84%
Mar 31, 2025
Point72 Asset Management, L.P.
4.41M
5.04%
+4.27M
+3048.93%
Jun 06, 2025
Logos Global Management LP
3.50M
4%
+500.00K
+16.67%
Mar 31, 2025
State Street Global Advisors (US)
3.45M
3.93%
+125.33K
+3.77%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.39M
3.87%
-395.42K
-10.45%
Mar 31, 2025
Deerfield Management Company, L.P.
3.27M
3.73%
+531.55K
+19.43%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
Tema Oncology ETF
1.99%
ALPS Medical Breakthroughs ETF
1.47%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
SPDR S&P Biotech ETF
0.61%
Direxion Daily S&P Biotech Bull 3X Shares
0.35%
ProShares Ultra Nasdaq Biotechnology
0.21%
Invesco Nasdaq Biotechnology ETF
0.19%
iShares Biotechnology ETF
0.17%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.12%
iShares Russell 2000 Growth ETF
0.12%
Mehr Anzeigen
Tema Oncology ETF
Anteil1.99%
ALPS Medical Breakthroughs ETF
Anteil1.47%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.88%
SPDR S&P Biotech ETF
Anteil0.61%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.35%
ProShares Ultra Nasdaq Biotechnology
Anteil0.21%
Invesco Nasdaq Biotechnology ETF
Anteil0.19%
iShares Biotechnology ETF
Anteil0.17%
JPMorgan BetaBuilders US Small Cap Equity ETF
Anteil0.12%
iShares Russell 2000 Growth ETF
Anteil0.12%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
